The real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland – A follow-up study after four years of observation
Efficacy was comparable across subgroups. Estimated treatment persistence at four years was 70 %. Treatment safety was comparable to previous literature. Adverse events were more frequent in subjects aged 50 years or older at treatment initiation.
Authors
- Marja Niiranen (ORCID: https://orcid.org/0000-0001-8674-020X)
- Hanna Kuusisto (ORCID: https://orcid.org/0000-0002-3697-4961)
- Merja Soilu‐Hänninen (ORCID: https://orcid.org/0000-0001-6930-0229)
- Sari Atula (ORCID: https://orcid.org/0000-0003-1293-9325)
- Mervi Ryytty (ORCID: https://orcid.org/0009-0003-3814-371X)
- Ilkka Rauma (ORCID: https://orcid.org/0000-0002-3275-9631)
- Sini M. Laakso (ORCID: https://orcid.org/0000-0002-0104-2849)
- Matias Viitala (ORCID: https://orcid.org/0000-0003-2854-2410)
- Visa Manni
Institutions
- University of Helsinki (FI)
- Oulu University Hospital (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Kuopio University Hospital (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1016/j.msard.2025.106724
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- Merck
- Merck KGaA